

Curriculum Vitae

Paul Eliezer Oberstein, MD, MS

Contact Information

Home address: 664 W 232nd Street, Bronx, NY 10463
Office address: 240 East 38th Street, 20th Floor, New York, NY 10016
Work phone: 212-731-6120
Cell phone: 646-599-4083
Work email address: paul.oberstein@nyulangone.org
Web page: <https://nyulangone.org/doctors/1265686075>

Additional Information

Place of birth: Allentown, PA, USA

Current Appointments and Leadership Positions

Faculty Appointment

12/2021 Associate Professor (Clinical), Dept of Medicine, NYU Langone Health, NY
03/2018 Member, Perlmutter Comprehensive Cancer Center, New York, NY

Hospital Appointment

03/2018 Attending Physician, NYU Langone Health, NY

Administrative Leadership Positions

03/2024 Service Chief, GI Oncology, Perlmutter Cancer Center, NYU, NY
09/2024 Co-Director, Pancreas Disease Center, NYU Langone Health, NY
03/2018 Co-Leader, GI Disease Management Group, PCC, New York, NY

Education and Training

Education

09/2000		Biophysics	Bar-Ilan University	Israel
06/2002	BS	Biochemistry	University of Maryland	College Park, MD
06/2006	MD	Medicine	Ohio State University	Columbus, OH
05/2015	MS	Biostatistics	Columbia University	New York, NY

Postdoctoral Training

06/2006-06/2009 Resident, Internal Medicine, Temple University Hospital, Philadelphia, PA
06/2010-06/2013 Fellow, Hematology and Oncology, Columbia University, NY, NY
05/2012-06/2014 Clinical Research Fellow, Olive Lab, Columbia University, New York, NY
06/2013-05/2015 Patient Oriented Research Fellowship, Columbia University, New York, NY

MERCK EX1141

Merck Sharp & Dohme LLC v. The Johns Hopkins University

IPR2024-00240

Specialty Certification

2009	American Board of Internal Medicine, Internal Medicine
2014	American Board of Internal Medicine, Medical Oncology

Licensure

2010-	New York	#257682
2006-2010	Pennsylvania	

Previous Appointments and Leadership Positions

Faculty Academic Appointments

03/2018-11/2021	Assistant Professor (Clinical), Dept. of Medicine, NYU Langone Health, NY
07/2013-02/2018	Assistant Professor (at CUMC), Dept. of Medicine, Columbia University, NY
06/2017-03/2018	Member, Irving Comprehensive Cancer Center, New York, NY.

Hospital Appointments

07/2013-02/2018	Assistant Attending Physician, NYP Hospital, New York, NY.
-----------------	--

Administrative Leadership Positions

03/2018- 2/2024	Director, GI Oncology, Perlmutter Cancer Center, NYU, NY
03/2018 -8/2024	Assistant/ Interim Director, Pancreatic Cancer Center, PCC, New York, NY
06/2012-06/2013	Chief Fellow in Hematology/Oncology, Columbia University, New York.

Other Professional Positions

N/A

Awards, Honors, and Memberships in Honorary Societies

Internal

06/2003	OSU Medical School, Roessler Fellowship presented for outstanding research project.
05/2006	OSU Medical School, Landacre Society for Medical Student Research.
06/2013	Columbia University, Patient Oriented Research Scholar.

External

06/2013	ASCO Conquer Cancer Foundation, Young Investigator Award
07/2019	NCI, 2019 Cancer Clinical Investigator Team Leadership Award
01/2023	National Pancreas Foundation, Nobility in Science Award

Research Activity

Research Activities

My major research activities include:

1. Building collaborative teams to design and implement novel translational clinical trials in pancreatic and other GI cancers.
2. Developing team-based approaches to improving care delivery and multi-disciplinary collaborative care in GI cancer patients.
3. Advancing novel therapies to support patient quality of life and outcomes including focus on physical activity, diet and novel therapies in GI cancers.

My work in these areas is focused on improving outcomes for patients with these recalcitrant cancers.

Grant History

Grants and Clinical Trials

Ongoing Research Support

Completed Research Support

National Institution of Health- 1P20CA252728-02 Ahn (PI) 9/17/20-8/31/24
 NYU Cancer Health Disparity (CHD) SPORE
 Role- Co Project Lead of Project 2. Multidisciplinary evaluation of tumor microbiome in orodigestive tract cancers.
 3% effort.

Merck Investigator Studies Program Oberstein (PI) 7/1/20- 12/31/2023
 Sponsored Research Project
A phase II study of lenvatinib, a multi-targeted tyrosine kinase inhibitor, combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies
 Role: PI of multi-center trial.
 5% effort. (project transferred from previous PI who left institution).

Pancreatic Cancer Action Network Simeone (PI) 2/1/20-1/31/24
 Precision Promise Clinical Trial Consortium.
 Role- Co-PI of NYU site in multi-institutional clinical trial network for advanced pancreatic cancer.
 5% effort.

National Cancer Institute (NCI)- RN 01327 Neel (PI) 3/1/2019-2/28/2021
 Cancer Center Support Grant P30 supplement- CCITLA (Oberstein)
 Role- PI of supplemental award to Cancer Center Support Grant to develop collaborative clinical trials.
 15% effort.

Pancreatic Cancer Action Network Wang (PI) 7/1/17- 6/30/19
 Translational Research Grant
Targeting cholinergic receptors to suppress pancreatic cancer.
 Total grant: \$300,000.
 Role- Co-PI and lead of clinical component. 10% effort.

UG1 CA189960-01 Schwartz (PI) 2017-2018
 Supplemental Contract Award- Parent NCORP Grant UG1 CA189960-01
Project Title: Columbia University Minority/Underserved Site NCI Community Oncology Research Program, NCI PDX Study Tissue Supplement.
 In this project, I will coordinate collection of tissue and blood samples from 30 newly diagnosed rare cancer patients for development of models in the NCI PDX program.
 Direct Funding: \$90,000 year based on accrual, renewable for 1 additional year.

Role: Project PI. 10% effort.

Merck Investigator Studies Program Oberstein (PI) 1/1/17-2/28/18
Sponsored Research Project
Phase II study of chemotherapy and immune checkpoint blockade with Pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma.
Total Contract: \$987,544.00.
Role: PI of multi-center trial. 10% effort.

Irving Institute for Clinical and Translational Research Han (PI) 3/1/17-2/28/18
Precision Medicine Pilot Award
Precision T cell receptor based therapies in cancer treatment.
Role: Collaborator. Led development of the clinical protocol and IRB submission and patient recruitment.

Merck Investigator Studies Program Oberstein (PI) 8/1/17-2/28/18
Sponsored Research Project
Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent Azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.
Total Contract: \$987,537.30.
Role: PI. 10% effort.

KL2 TR000081 Ginsberg (PI) 7/1/15-6/30/17
Clinical and Translational Science Award
Developing Validated Models to Measure Tumor Associated Cachexia in Pancreatic Cancer
The goal of this mentored research study is to assess the correlation between various imaging and pathological measurements to measure tumor associated cachexia.
Direct Cost: \$75,000.
Role: PI of mentored project. 50% effort.

UG1 CA189960-01 Schwartz (PI) 2015-2016
Supplemental Award- Parent NCORP Grant UG1 CA189960-01
Project Title: Columbia University Minority/Underserved Site NCI Community Oncology Research Program, NCI PDX Study Supplement.
In this project, I coordinated collection of blood samples from 100 newly diagnosed advanced cancer patients for support of the NCI PDX program.
Total Cost: \$100,000.
Role: Project PI. 10% effort.

Young Investigator Award (YIA) Oberstein (PI) July 2013- June 2014
American Society of Clinical Oncology
Evaluation of the therapeutic effect of a small molecule inhibitor of the oncoprotein BMI1 in pancreatic cancer.
Mentor: Kenneth Olive, PhD
Sponsor: Alfred I. Neugut, MD, PhD
Total Cost: \$50,000.
Role: PI, 50% effort.

Active Clinical Trials

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors. 2024-
Sponsor: Revolution Medicines, Inc. NCT06040541

Role: Site Principal Investigator

A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors. 2024-
Sponsor: Eli Lilly. NCT06586515

Role: Site Principal Investigator

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer. 2023-

Sponsor: NYU. NCT05984602

Role: Principal Investigator, Investigator Initiated, IND Holder

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer. 2022- 2025

Sponsor: NYU. NCT05483075

Role: Principal Investigator, Investigator Initiated

A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02). 2023-

Sponsor: AMAL Therapeutics. NCT05846516

Role: Global Coordinating Principal Investigator

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE), SWOG S2303. 2023-

Sponsor: SWOG (NCTN). NCT06203600

Role: National Co-Chair, Site co-Investigator

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). 2024-

Sponsor: Revolution Medicine Inc. NCT06625320

Role: Site Principal Investigator

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations. 2024-

Sponsor: ECOG (NCTN). NCT04548752

Role: Site Principal Investigator

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation. 2022-

Sponsor: ECOG (NCTN). NCT04858334

Role: Site Principal Investigator

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer. 2022-2024.

Sponsor: Janssen Therapeutics. NCT05379595

Role: Site Principal Investigator

A022104 The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer. 2024-

Sponsor: Alliance (NCTN). NCT05610163

Role: **Site Co-Investigator**

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers. 2024-

Sponsor: Merck. NCT06428409

Role: **Site Principal Investigator**

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination with Anti-cancer Agents in Adult Participants with Tumours Harboring a KRASG12D Mutation. 2024-

Sponsor: Astra Zeneca. NCT06599502

Role: **Site Co-Investigator**

A phase II study (with safety run-in) of ALX148 in combination with cetuximab and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer. 2023-

Sponsor: AGICC. NCT05167409

Role: **Site Co-Investigator**

A Randomized Open-Label Phase 3 Study of XL09 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer (STELLAR). 2023-2024.

Sponsor: Exelixis. NCT05425940

Role: **Site Principal Investigator**

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy. 2021-

Sponsor: Mirati. NCT04793958

Role: **Site Principal Investigator**

Phase II pilot study of FOLFOXIRI plus panitumumab in metastatic RAS wild-type, left-sided colorectal cancer. 2020- 2024

Sponsor: AGICC. NCT04169347

Role: **Site Co-Investigator**

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01). 2022-2024.

Sponsor: Amal Therapeutics. NCT04046445

Role: **Site Principal Investigator**

BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue From Subjects With Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing, 2021-

Sponsor: A2 Therapeutics Inc. NCT04981119

Role: Site Co-Investigator

Orodigestive (ODT) Cancer Multi-Ethnic Cohort. 2020-

Sponsor: NYU (NCI).

Role: Principal Investigator

Completed Clinical Trials (partial list)

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies. 2018-2023.

Sponsors: Eisai and Merck. NCT03321630

Role: Principal Investigator, Investigator Initiated, IND Holder

A Phase 3, randomized, double-blind study of pamrevlumab or placebo in combination with gemcitabine plus nab-paclitaxel as neoadjuvant treatment in patients with locally advanced, unresectable pancreatic cancer. 2020-2023.

Sponsor: Fibrogen. NCT03941093

Role: Site Principal Investigator

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT). 2020-2022.

Sponsor: Corcept. NCT04329949

Role: Site Principal Investigator

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumor (LEAP-005). 2019-2021.

Sponsor: Merck.

Role: Site Principal Investigator

A Phase 2 Study of APX005M in Combination with Concurrent Chemo-radiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers. 2021-2023.

Sponsor: Apexigen. NCT03165994

Role: Site Principal Investigator

A Phase 1b Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients with Metastatic Pancreatic Cancer. 2020-2023.

Sponsor: PANCAN and Novartis. NCT

Role: Principal Investigator, Investigator Initiated

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer. 2018-2022.

Sponsors: Stand Up to Cancer, BMS.

Role: Site Principal Investigator

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies. 2020-2022.

Sponsor: Arcus Biosciences.

Role: Site Principal Investigator

A Phase 1 b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer. 2021-2023.

Sponsor: Arcus Biosciences.

Role: Site Principal Investigator

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). 2021-2023.

Sponsor: Novartis.

Role: **Site Principal Investigator**

A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma. 2021-2023.

Sponsor: Aravive.

Role: **Site Principal Investigator**

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without Chemotherapy in Patients with Advanced Pancreatic Cancer. 2018-2020.

Sponsor: BMS. NCT

Role: **Site Principal Investigator**

Clinical Activity

I lead the GI Oncology practice within the Perlmutter Cancer Center at NYU Langone Health. I have primary oversight of 10 physicians and patient care teams in Manhattan, Brooklyn, and Long Island. Our group sees over 1500 new unique GI Cancer patients per year and has over 350 encounters a week. I oversee weekly meetings with multidisciplinary teams including medical oncology, radiation oncology, palliative care, social work, nutrition, and research to provide group oversight and expert care. I devote 50% of my effort in the outpatient clinic focusing on GI malignancies with emphasis on pancreatic, gastric and colon cancers and 2 weeks per year on the inpatient Oncology service. Since coming to NYU in 2018, I have instituted rapid access referrals in our clinics, leading to increased multidisciplinary collaboration, increased clinical trial participation and increased volumes by over 100%.

Education Activity

My educational activities are focused on training medical oncology fellows and Internal Medicine residents in oncology care and clinical research. In addition to mentoring in my clinics, I have aggressively increased didactic lectures in GI cancers and engaged trainees broadly in exploring clinical questions in GI Oncology. I have mentored multiple trainees and collaborated with several basic science partners to help lab trainees gain clinical and translational exposure and develop new projects.

Teaching Activities (see description)

2020- 2022	4 Part Lecture Series- Introduction to Clinical Research for Hematology/ Oncology fellows. Lecture series introducing regulatory and statistical principles of clinical and translational research for fellows. 40 hours in year 1.
2020- 2025	Fellowship Didactics Teaching in fellowship program, 3-4 lectures per year to Medical Oncology and Radiation Oncology trainees in GI Cancers.
2021- 2025	Translating Cancer Discovery into Clinical Practice, BMSC-GA 4422 Graduate level seminar in translational cancer research and application. Annual seminar in GI Cancer translational research.

12/2018- 2025	Teaching in medical school curriculum, Oncology Small Group Session Leader, medical students, 4 hours per year.
7/2013- 11/2017	Teaching to various fellows, Columbia University Medical Center including medical oncology fellows (3 hours/year), GI fellows (2 hours), palliative care fellows (2 hours), 12 hours per year.
08/2014- 07/2017	Teaching in medical school curriculum, course lecturer (Pancreatic Cancer) and group discussion leader, The Body in Health and Disease, Pathophysiology of Oncology, Columbia University Medical School, 6 hours per year.
09/2017- 05/2017	Teaching in medical school curriculum, Clerkship Supervisor, Foundation of Clinical Medicine 1 Clerkship, Columbia University. 6 hours per year.

Curriculum development and other innovative educational activities

01/2020	Received NCI funded award to design and implement an introductory 4 part lecture series on clinical and translational research. Designed lectures covering trial design, basic biostatistics in collaboration with additional faculty, regulatory considerations, and practical applications. 40 hours in first year.
10/2019	Developed new didactic course for fellowship program, recruited 9 faculty members to participate, designed the curriculum and led lectures to provide a comprehensive course in all aspects of GI cancers including pathology, genetics, and translational research. 20 hours in first year.

Invited Talks and Teaching of Peers

Internal

Sponsored by NYU Langone Health

03/2018- current	Lead or co-lead multidisciplinary educational tumor boards at NYU Langone Health. These include primary oversight for weekly GI Oncology tumor board with over 40 participants from all campuses; leadership of monthly Neuroendocrine Oncology Tumor Board, leadership role in weekly Pancreatic Cancer tumor board, and participation in weekly Multidisciplinary Liver Radiology Conference.
11/13/2024	Sports Health Grand Rounds, Exercise is Medicine, NYU Langone Health. "Cancer and Exercise"
May 2023	Pancreatic Cancer Center Research Seminar Series. "Clinical Trials in Pancreatic Cancer- Updates and Opportunities"
1/23/24	GI Grand Rounds, Division of Gastroenterology, NYU Langone. "Novel Treatment Paradigms in GI Cancers- 2023"
11/6/2018	Oncology Grand Rounds, NYU Winthrop, "Multidisciplinary Approached to Localized Disease in Pancreatic Cancer"

10/30/2018 GI Grand Rounds, Division of Gastroenterology, “Progress in Pancreatic Cancer”

Sponsored by all other NYU schools

1/10/2025 NYU Langone Health Big Gut Seminar Series in Pancreatic Diseases. “Adoptive Cell Therapy in Pancreatic Cancer: CAR-T, TILs and Beyond”

March 2024 NYU Langone Health, Community Webinar on **Colorectal Cancer: Prevention, Screening & Treatment**. “Advancements in Treatment Options in Colon Cancer”

5/5/23 NYU Langone Health Big Gut Seminar Series in Pancreatic Diseases. “Novel Clinical Trials in Pancreatic Cancer”

Feb 2020- Invited lecture, Colorectal Cancer Immunology, BIOL-GA 1011, Spring 2020 Advanced Immunology, Gastrointestinal Immunology Course. Course Director: Carol Shoshkes Reiss, PhD.

External to NYU Langone Health and all other NYU schools

11/14/2024 “Exploring Combination Therapies Utilizing KRAS G12D Inhibitors in Pancreas Cancer” **Inaugural New York Pancreatic Cancer Consortium**.

September 2024 “Mechanisms of Resistance to KRAS Inhibition in Pancreas Cancer”. “IL-1b Targeted Therapy in PDAC: Biological Correlates and Neoadjuvant Therapy”. “Amivantamab, an EGFR/C-MET Bispecific in Colorectal Cancer.” “RMC-9805, A KRAS G12D Inhibitor for KRAS G12D-Mutated Solid Tumors”. **Invited lectures at DAVA Oncology 2024 Bermuda GI Summit**.

May 2023 “Novel Clinical Trials in Pancreatic Cancer.” **Invited lecture at Taipei Veterans General Hospital, Taipei City, Taiwan**.

Feb 2022 “Colorectal Cancer- Updates and Novel Agents” **OncLive Institutional Perspectives in Cancer Series, New York**.

May 2018 “Incorporating Novel Agents and Sequencing Approaches in Advanced Pancreatic Neoplasms.” **OncLive State of the Science Summit, New York**.

Jan 2015 Visiting Professor Lecture, “Pancreatic Cancer in 2015”. Department of Radiology, **University of Vermont Medical Center**.

March 2015 Cancer Center Grand Rounds. “Pancreatic Cancer; Progress and Challenges.” Norris Cotton Cancer Center, **Dartmouth-Hitchcock Medical Center**.

Feb 2013 Oncology Seminar Series. “Epithelial Stromal Interactions in a Mouse Model of Pancreatic Cancer.” **Weill Cornell Medical Center, NY**.

June 2013 Hematology/Oncology Grand Rounds Seminar. “Paradoxical Acceleration of Pancreatic Cancer Due to Hedgehog Inhibition.” Department of Medicine, **Columbia University Medical Center**.

Mentoring and Advising

Predoctoral students supervised and/or mentored

2019- 2023 Emma Kurz, NYU Langone MD/PhD program, Advisor on thesis committee and translational mentor for clinical trial development.
Current Position: Internal Medicine Resident, Mass General Hospital

Postdoctoral students supervised and/or mentored

07/2024- Alessandro Leal, NYU Hematology/Oncology program, clinical and translational research mentor.

07/2020- Peter Yu, NYU Hematology/Oncology program, clinical and translational research mentor.
Mentee was awarded a Young Investigator Award from ASCO (2022) and KL2 Career Development Award (2024).
Current Position: Instructor, NYU Langone Health

07/2019- 2023 Chengwei Peng, NYU Hematology/Oncology program, clinical and translational research mentor.
Mentee was awarded a Young Investigator Award from ASCO (2022).
Current Position: Assistant Professor, Feinberg School of Medicine, Chicago, IL.

07/2018- 2021 Benjamin Krantz, NYU Hematology/Oncology program. Clinical mentor.
Current Position: Clinical Assistant Professor, NYU Langone Health. Biotech executive.

09/2018- 2021 Ajay Prakash, NYU Hematology/Oncology program. Clinical research mentor.
Current Position: Assistant Professor, University of Minnesota Medical School

08/2016- 2018 Ruth White, Columbia University. Clinical mentor, Instructor- Columbia University.
Mentee was awarded a Young Investigator Award from ASCO (2018).
Current Position: Assistant Professor, NYU Langone Health, New York.

07/2016- 2018 Rachael Safyan, Columbia University. Clinical and Research mentor, Assistant Professor- Columbia University.
Mentee was awarded a Young Investigator Award from ASCO (2017).
Current Position: Assistant Professor, University of Washington, Fred Hutch Cancer Center, Seattle WA.

Faculty mentored

07/2018- 2022 Despina Siolas, NYU Division of Hematology/Medical Oncology.
Clinical mentor and faculty advisor on K08 (CA241341).
Current Position: Assistant Professor, Cornell University, New York.

Institutional, Local/National Service and Related Activity

Institutional Service

2014- 2018 Member, Protocol Review and Monitoring Committee, Herbert Irving Comprehensive Cancer Center.

2015- 2018 Member, Clinical Competency Committee, Division of Hematology/Oncology, Columbia University.

2008-2009 Member, Pharmacy and Therapeutics Committee, Temple University Hospital.

Professional Service

Professional Service for Professional Organizations

2010-	Member, American Society of Clinical Oncology
2012-	Member, American Association of Cancer Research
2013-	Member, Southwest Oncology Group Network.
2013-	Member, Gastrointestinal Committee, Southwest Oncology Group.
2018-	Member, Clinical Trial Consortium Committee, Precision Promise, Pancreatic Cancer Action Network.
2018-	Member, Supportive Care Committee, Precision Promise, Pancreatic Cancer Action
2019-2020	Member, Arm Selection Committee, Precision Promise.

Peer Review Groups, Grant Application Review Groups, and Study Sections

2013- 2015	PCORI Institute, Washington, DC- Stakeholder Reviewer
2015- 2018	Irving Institute of Clinical and Translational Research- Collaborative and Multidisciplinary Pilot Research Grants- Scientific Reviewer.
2015- 2018	Irving Institute of Clinical and Translational Research Clinical Trials Pilot Award- Scientific Reviewer.

Advisory Boards and Consultant Positions

2023-	GI Steering Council Member- AstraZeneca Partners in Care Network
2017- 2023	US Gastric Advisory Board- Merck
2018- 2021	Scientific Advisory Board- Tyme Inc.
2019- 2021	Ad Hoc Member, National Steering Committee, PANC003 Trial (NCT03504423).
2020- 2022	Scientific Advisory Board- Rubius Therapeutics
2024-	Scientific Council- Ipsen Biopharmaceuticals
2023-	Steering Committee and Global PI- Amal Therapeutics

Organizing Roles in Scientific Meetings

2013-2017	Co-Organizer, Gig Shaw Symposium on Pancreatic Disease at the Pancreas Center of Columbia University. With a co-organizer, led all aspects of planning for a highly successful biennial conference of external and internal speakers in pancreatic cancer (2013, 2015, 2017)
-----------	--

Editorial and Journal Positions

Ad Hoc	JAMA, Journal of Clinical Oncology, Therapeutic Advances in Gastroenterology, Gastroenterology, JNCCN, Oncologist, Cancer Discovery, Clinical Cancer Research.
--------	--

Community Service, Volunteer Activities, and Teaching of Patients

2016-	Volunteer, Lustgarten Foundation.
-------	-----------------------------------

Military Service

N/A

Bibliography

Publications: Orcid ID: 0000-0001-5918-6004

Peer-reviewed Publications

1. Borazanci, Erkut H; Bahary, Nathan; Chung, Vincent; Huyck, Timothy K; Kio, Ebenezer A; Chiorean, Elena Gabriela; Skeel, Roland T; Alese, Olatunji B; Cardin, Dana B; Fountzilas, Christos; Hanna, Wahid T; Leal, Alexis D; Lee, Valerie; Noonan, Anne M; Philip, Philip A; Wainberg, Zev A; Pashova, Hristina; Mann, Grace; **Oberstein, Paul E**. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024 Nov 04;29(11):957-965.
2. Habib JR, Kinny-Köster B, Javed AA, Zelga P, Saadat LV, Kim RC, Gorris M, Allegrini V, Watanabe S, Sharib J, Arcerito M, Kaiser J, Lafaro KJ, Tu M, Bhandre M, Shi C, Kim MP, Correa C, Daamen LA, **Oberstein PE**, Schmidt CM, Hanna NN, Allen P, Loos M, Shrikhande SV, Molenaar IQ, Frigerio I, Katz MHG, Soares KC, Miao Y, Del Chiaro M, He J, Hackert T, Salvia R, Büchler MW, Castillo CF, Besselink MG, Marchegiani G, Wolfgang CL; Verona IPMN Consortium. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. J Clin Oncol. 2024 Sep 10;JCO2302313. doi: 10.1200/JCO.23.02313. Epub ahead of print. PMID: 39255450.
3. Peng C, Saffo S, **Oberstein PE**, Shusterman M, Thomas C, Becker DJ, Berlin JD, Leichman LP, Boursi B, Nagar AB, Yu S. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. J Natl Compr Canc Netw. 2024 Sep 5;22(8):521-527. doi: 10.6004/jncn.2024.7029. PMID: 39236754.
4. Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, Chiorean EG, Skeel RT, Alese OB, Cardin DB, Fountzilas C, Hanna WT, Leal AD, Lee V, Noonan AM, Philip PA, Wainberg ZA, Pashova H, Mann G, **Oberstein PE**. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024 Nov 4;29(11):957-965. doi: 10.1093/oncolo/oyae210. PMID: 39191530; PMCID: PMC11546724.
5. Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, **Oberstein PE**, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouracil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. J Clin Oncol. 2024 Nov;42(31):3692-3701. doi: 10.1200/JCO.23.02659. Epub 2024 Aug 1. PMID: 39088774.
6. **Oberstein PE**, Dias Costa A, Kawaler EA, Cardot-Ruffino V, Rahma OE, Beri N, Singh H, Abrams TA, Biller LH, Cleary JM, Enzinger P, Huffman BM, McCleary NJ, Perez KJ, Robinson DA, Schlechter BL, Surana R, Yurgelun MB, Wang SJ, Remland J, Brais LK, Bollenrucher N, Chang E, Ali LR, Lenehan PJ, Dolgalev I, Werba G, Lima C, Keheler CE, Sullivan KM, Dougan M, Hajdu C, Dajee M, Pelletier MR, Nazeer S, Squires M, Bar-Sagi D, Wolpin BM, Nowak JA, Simeone DM, Dougan SK. Blockade of IL1 β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor. Cancer Immunol Res. 2024 Sep 3;12(9):1221-1235. doi: 10.1158/2326-6066.CIR-23-1073. PMID: 38990554; PMCID: PMC11369625.
7. Fan X, Monson KR, Peters BA, Whittington JM, Um CY, **Oberstein PE**, McCullough ML, Freedman ND, Huang WY, Ahn J, Hayes RB. Altered salivary microbiota associated with high-sugar beverage consumption. Sci Rep. 2024 Jun 11;14(1):13386. doi: 10.1038/s41598-024-64324-w.

PMID: 38862651; PMCID: PMC11167035.

8. Dong S, Agarunov E, Fasullo M, Kim KY, Khanna L, Haber G, Janec E, Simeone D, **Oberstein P**, Gonda T. Somatic Mutational Analysis in Endoscopic Ultrasound-Guided Biopsy of Pancreatic Adenocarcinoma: Assessing Yield and Impact. Am J Gastroenterol. 2024 Aug 1;119(8):1636-1639. doi: 10.14309/ajg.0000000000002786. Epub 2024 Mar 28. PMID: 38546128.
9. Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, Sender N, Negri T, Gautier K, Ge L, Fan W, Xie M, Sethi A, Schroepe B, Tan AC, Park H, **Oberstein PE**, Shah MA, Raufi AG. Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma. JAMA Oncol. 2023 Oct 19;. doi: 10.1001/jamaoncol.2023.4423. [Epub ahead of print] PubMed PMID: 37856106
10. Wan S, Zhao E, Weissinger D, Krantz BA, Werba G, Freeman D, Khanna LG, Siolas D, **Oberstein PE**, Chattopadhyay PK, Simeone DM, Welling TH. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Front Immunol. 2023;14:1067352. doi: 10.3389/fimmu.2023.1067352. Erratum in: Front Immunol. 2023 Mar 23;14:1177713. doi: 10.3389/fimmu.2023.1177713. PMID: 36798126
11. Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Wang L, Lim HB, Oh G, Jing X, Beri N, Khanna L, Gonda T, **Oberstein P**, Hajdu C, Loomis C, Heguy A, Sherman MH, Lund AW, Welling TH, Dolgalev I, Tsigos A, Simeone DM. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat Commun. 2023 Feb 13;14(1):797. doi: 10.1038/s41467-023-36296-4. PubMed PMID: 36781852; PubMed Central PMCID: PMC9925748
12. Um CY, Peters BA, Choi HS, **Oberstein P**, Beggs DB, Usyk M, Wu F, Hayes RB, Gapstur SM, McCullough ML, Ahn J. Grain, Gluten, and Dietary Fiber Intake Influence Gut Microbial Diversity: Data from the Food and Microbiome Longitudinal Investigation. Cancer Res Commun. 2023 Jan;3(1):43-53. doi: 10.1158/2767-9764.CRC-22-0154. eCollection 2023 Jan. PubMed PMID: 36968219
13. Monson KR, Peters BA, Usyk M, Um CY, **Oberstein PE**, McCullough ML, Purdue MP, Freedman ND, Hayes RB, Ahn J. Elevated dietary carbohydrate and glycemic intake associate with an altered oral microbial ecosystem in two large U.S. cohorts. Cancer Res Commun. 2022 Dec;2(12):1558-1568. doi: 10.1158/2767-9764.crc-22-0323. Epub 2022 Dec 5. PubMed PMID: 36567732
14. Everett JN, Dettwyler SA, Jing X, Stender C, Schmitter M, Baptiste A, Chun J, Kawaler EA, Khanna LG, Gross SA, Gonda TA, Beri N, **Oberstein PE**, Simeone DM. "Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting." Cancer Medicine. 2022 Jul 30. PMID: 35906821
15. Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, **Oberstein P**, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract. 2021 Oct;17(10):607-614. doi: 10.1200/OP.20.00701. Epub 2021 Feb 3. PubMed PMID: 33534616
16. Masuda K, Kornberg A, Miller J, Lin S, Suek N, Botella T, Secener KA, Bacarella AM, Cheng L, Ingham M, Rosario V, Al-Mazrou AM, Lee-Kong SA, Kiran RP, Stoeckius M, Smibert P, Del Portillo A, **Oberstein PE**, Sims PA, Yan KS, Han A. "Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer." JCI Insight. 2022 Apr 8;7(7). PMID: 35192548
17. Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliu J, Ponz-Sarvisé M, Abad DG, **Oberstein P**, Alistar A, Muñoz A, Geva R, Guillén-Ponce C, Fernandez MS, Peled A, Chaney M, Gliko-Kabir I, Shemesh-Darvish L, Ickowicz D, Sorani E, Kadosh S, Vainstein-Haras A, Hidalgo M. "Motixafortide

and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.” Clinical Cancer Research. 2021 Sept 15;27(18). PMID: 34253578

18. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, **Oberstein P**, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. *J Clin Oncol*. 2020 Sep 20;38(27):3185-3194. doi: 10.1200/JCO.20.00590. Epub 2020 Jul 24. PMID: 32706635; PMCID: PMC7499614.
19. Everett JN, Burgos G, Chun J, Baptiste A, Khanna LG, **Oberstein PE**, Simeone DM. Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma. *Cancer*. 2021 Jul 1;127(13):2271-2278. doi: 10.1002/cncr.33500. Epub 2021 Mar 15. PMID: 33721345.
20. Payen, Thomas; **Oberstein, Paul E**; Saharkhiz, Niloufar; Palermo, Carmine F; Sastra, Stephen A; Han, Yang; Nabavizadeh, Alireza; Sagalovskiy, Irina R; Orelli, Barbara; Rosario, Vilma; Desrouilleres, Deborah; Remotti, Helen; Kluger, Michael D; Schroepe, Beth A; Chabot, John A; Iuga, Alina C; Konofagou, Elisa; Olive, Kenneth P. “Harmonic Motion Imaging Of Pancreatic Tumor Stiffness Indicates Disease State And Treatment Response”. Clinical Cancer Research. 2020 Mar 15; 26(6):1297-1308. PMID:31831559
21. Nabavizadeh A, Payen T, Iuga AC, Sagalovskiy IR, Desrouilleres D, Saharkhiz N, Palermo CF, Sastra SA, **Oberstein PE**, Rosario V, Kluger MD, Schroepe BA, Chabot JA, Olive KP, Konofagou EE. “Noninvasive Young’s modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo.” Theranostics. 2020 Mar 15;10. PMID: 32292518
22. Le, Dung T; Picozzi, Vincent J; Ko, Andrew H; Wainberg, Zev A; Kindler, Hedy; Wang-Gillam, Andrea; **Oberstein, Paul**; Morse, Michael A; Zeh, Herbert J; Weekes, Colin; Reid, Tony; Borazanci, Erkut; Crocenzi, Todd; LoConte, Noelle K; Musher, Benjamin; Laheru, Dan; Murphy, Aimee; Whiting, Chan; Nair, Nitya; Enstrom, Amanda; Ferber, Sandy; Brockstedt, Dirk G; Jaffee, Elizabeth M. “Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)”. Clinical cancer research. 2019;25(18):5493-5502. PMID: 31126960.
23. Alvarez, Mariano J; Yan, Pengrong; Alpaugh, Mary L; Bowden, Michaela; Sicinska, Ewa; Zhou, Chensheng W; Karan, Charles; Realubit, Ronald B; Mundi, Prabhjot S; Grunn, Adina; J  nger, Dirk; Chabot, John A; Fojo, Antonio T; **Oberstein, Paul E**; Hibshoosh, Hanina; Milsom, Jeffrey W; Kulke, Matthew H; Loda, Massimo; Chiosis, Gabriela; Reidy-Lagunes, Diane L; Califano, Andrea. “Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’”. Nature genetics. 2019;51(10):1427-1428. PMID: 31548719
24. Neff BA, **Oberstien E**, Lorenz M, Chaudhury AR, Welling DB, Chang LS. “Cyclin D(1) and D(3) expression in vestibular schwannomas.” *Laryngoscope*. 2006 Mar;116(3):423-6. PMID:16540902.
25. **Oberstein PE**, Kenney B, Krishnamoorthy SK, Woo Y, Saif MW. “Metastatic Gastric Large Cell Neuroendocrine Carcinoma: A Case Report and Review of Literature.” Clin Colorectal Cancer. 2012 Sept;11(3):218-223. PMID:22421002.
26. **Oberstein PE**, Hershman DL, Chabot JA, Insel BJ, Khanna L, Neugut AI. “Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population based study.” Cancer Investigation. 2013 Jun;31(5):316-22. PMID:23614655.

27. Horowitz DP, **Oberstein PE**, Gidea-Addeo D. "Use of adjuvant radiation therapy in the management of acinar cell carcinoma of the pancreas: results from the Survival, Epidemiology, and End Results database." Journal of Radiation Oncology. April 2014.
 28. Rhim AD*, **Oberstein PE***, Thomas DH*, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ." Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma." Cancer Cell. 2014 Jun 16;25(6):735-47. PMID:24856585.
 29. Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, **Oberstein PE**, Fine RL, Laheru DA, Goggins M. "Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer." Oncotarget. 2017 Jul 4;8(27):44073-44081. PMID: 28454122.
 30. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braith F, Ritch PS, Zalupski MM, Bahary N, **Oberstein PE**, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. "HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma." Journal of Clinical Oncology 2018 Feb 1;36(4):359-366. PMID: 29232172.
 31. Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, **Oberstein PE**, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Suflarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N. "Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours." Neuroendocrinology. 2018;107(3):237-245. PMID: 29991024.
 32. Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, **Oberstein PE**, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC. "Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness." Cancer Discovery. 2018 Nov;8(11):1458-1473. PMID: 30185628.
- Maurer C, Holmstrom SR, He J, Laise P, Su T, Ahmed A, Hibshoosh H, Chabot JA, **Oberstein PE**, Sepulveda AR, Genkinger JM, Zhang J, Iuga AC, Bansal M, Califano A, Olive KP. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut. 2019 Jun;68(6):1034-1043. doi: 10.1136/gutjnl-2018-317706. Epub 2019 Jan 18. PMID: 30658994; PMCID: PMC6509007.

Peer-reviewed reviews

1. **Oberstein PE**, Saif MW. "First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium." San Francisco, CA, USA. January 20-22, 2011." JOP. 2011 Mar 9;12(2):96-100. PMID:21386629.
2. **Oberstein PE**, Saif MW. "Novel Agents in the Treatment of Unresectable neuroendocrine Tumors. Highlights from the "2011 ASCO Annual Meeting." Chicago, IL, USA; June 3-7,2011." JOP. 2011 Jul 8;12(4):358-61. PMID:21737896.
3. **Oberstein PE**, Saif MW. "Safety and efficacy of everolimus in adult patients with neuroendocrine tumors." Clin Med Insights Oncol. 2012;6:41-51. PMID:22253554.

4. **Oberstein PE**, Remotti H, Saif MW, Libutti SK. "Pancreatic neuroendocrine tumors: entering a new era." JOP. 2012 Mar 10;13(2):169-73. PMID:22406593.
5. **Oberstein PE**, Saif MW. "Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors." JOP. 2012 Jul 10;13(4):368-71. PMID:22797391.
6. **Oberstein PE**, Saif MW. "Update on novel therapies for pancreatic neuroendocrine tumors." JOP. 2012 Jul 10;13(4):372-5. PMID:22797392.
7. **Oberstein PE**, Olive KP. "Pancreatic Cancer: Why is it so hard to treat?" Therapeutic Advances in Gastroenterology. 2013 Jul;6(4):321-37. PMID:23814611.
8. Manji GA, Olive KP, Saenger YM, **Oberstein P**. "Current and Emerging Therapies in Metastatic Pancreatic Cancer." Clin Cancer Res. 2017 Apr 1;23(7): 1670-1678. PMID: 28373365.
9. Siolas D, Morrissey C, **Oberstein PE**. "The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials." Journal of Pancreatology. 2020 Sept;3(3). PMID: 33133736

Non peer-reviewed publications

N/A

Media appearances

2020- <https://www.everydayhealth.com/cancer/colon-cancer/chadwick-boseman-s-death-highlights-changing-trends-in-colorectal-cancer>

Feb 2020- <https://www.medscape.com/viewarticle/925799>

Jan 2020- <https://www.self.com/story/ulcerative-colitis-colorectal-cancer>

Multiple- <https://www.survivornet.com/author/dr-paul-oberstein/>

Multiple- 2019: <https://provaeducation.com/profiles/paul-oberstein-md/Lbd113/>

3/8/19- Live Fox5 interview on pancreatic cancer.

2018- Onclive: <https://www.onclive.com/search?searchTerm=paul oberstein>

Abstracts (complete list <https://nyulangone.org/doctors/1265686075/paul-e-oberstein#publications>)

Oral and poster presentations

1. Nehal J. Lakhani, Davide Melisi, Vivek Subbiah, Natraj R. Ammakkanavar, Eileen M. O'Reilly, Philippe A. Cassier, Zev A. Wainberg, Austin G. Duffy, Amita Patnaik, Yutaka Fujiwara, **Paul E. Oberstein**, Rocio Garcia-Carbonero, Jennifer Wright, Aimee K. Lin, Jian Li, Michael D. Axelson, Ignacio Garrido-Laguna. "MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors." GI ASCO 2025. Abstract TPS845.
2. Alexander I. Spira, Kyriakos P. Papadopoulos, Dae W. Kim, Aparna R. Parikh, Minal A. Barve, John D. Powderly II, Alexander Starodub, John H. Strickler, Bob T. Li, **Paul E. Oberstein**, Faisal Hassan,

Michelle Yang, Mark McClelland, Satwant Lally, Wei Lin, Sophia Sohoni, David S. Hong. “Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.” GI ASCO 2025. Abstract 724.

3. Vincent J. Picozzi, Anna M. Varghese, **Paul E. Oberstein**, Manuel Hidalgo, Brian M. Wolpin, Kian-Huat Lim, Anna McGlothlin, Todd Graves, Michelle A. Detry, Mark Fitzgerald, Anna Bosse, Cassadie Moravek, Samantha Pedersen, Anna Berkenblit, Jian Chen, Ewa Carrier, Deyaa R. Adib, Donald A. Berry, Diane M. Simeone, Andrew H. Ko. “Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.” GI ASCO 2025. Abstract 673.
4. Kanwal P. Raghav, Eric Van Cutsem, Dirk Arnold, **Paul E. Oberstein**, Myung Ah Lee, Marcia Cruz-Correa, Eric X. Chen, Sae-Won Han, Rozita Abdul Malik, Cathy Eng, Victor Moreno, Sanjib Chowdhury, Ryota Iwasawa, Robert W. Schnepf, Rianka Bhattacharya, Patricia A. Lorenzini, Mahadi Baig, Filippo Pietrantonio, Joel R. Hecht. “Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study.” GI ASCO 2025. Abstract 197.
5. Jacquelyne Janean Gaddy, Gerald Li, Rachel B Keller-Evans, JENNIFER Marie MILLS, **Paul Eliezer Oberstein**, Pamela L. Kunz, Smruthy Sivakumar, David Bray. “Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).” ASCO Annual Meeting 2024. Abstract 4138.
6. Madeline Rose Miceli, Dalia Littman, Lena Masri, Daniel Jacob Becker, **Paul Eliezer Oberstein**. “Prognostic value of circulating tumor DNA testing in surgically resected pancreatic cancer.” ASCO Annual Meeting 2024. Abstract 4134.
7. Deirdre J. Cohen, Judith D. Goldberg, Lawrence P. Leichman, Tsvia Hochman, Elliot Newman, Kevin Lee Du, Alec Megibow, **Paul Eliezer Oberstein**, Raed Moh'd Taiseer Al-Rajabi, Aaron J. Scott, Tanios S. Bekaii-Saab, Wells A. Messersmith, Colin D. Weekes. “Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.” ASCO Annual Meeting 2024. Abstract 4175.
8. **Paul Oberstein**, Andrea Wang-Gillam, Anna Varghese, Andrew Ko, Andrew Hendifar, Allyson Ocean, Anna McGlothlin, Todd Graves, Scott Berry, Michelle Detry, Mark Fitzgerald, Anna Bosse, Cassadie Moravek, Kelly Feehan, Carrie Howland, Donald Berry, Diane Simeone, Vincent Picozzi. “Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy.” GI ASCO 2024. Abstract 675.
9. **Paul Oberstein**, Victor Moreno, Kanwal Raghav, Yong Sang Hong, Sae-Won Han, Yu-Li Su, Ying Yuan, Filippo Pietrantonio, Eric Van Cutsem, Cathy Eng, Joshua Curtin, Sanjib Chowdhury, Rianka Bhattacharya, Raymond Maul, Ryota Iwasawa, Robert Schnepf, Roland Knoblauch, Meena Thayu, Gwo Ho, Han Sang Kim. “Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.” GI ASCO 2024. Abstract 135.
10. Zev Wainberg, Gulam Manji, Nathan Bahary, Susanna Ulahannan, Shubham Pant, Nataliya Ubaha, **Paul Oberstein**, Lawrence Lu, Jennifer Scott, Wilson Wu, Joon Rhee, Dimitry Nuyten, Eileen O'Reilly. “ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naïve metastatic pancreatic adenocarcinoma.” GI ASCO 2024
11. Anwaar Saeed, Sarah Colby, **Paul Oberstein**, Dan Duda, Rajiv Agarwal, Colmar Figueroa-Moseley, Riha Vaidya, Joseph Unger, Katherine Guthrie, Flavio Rocha, Maheswari Senthil, Rachael Safyan, Zev Wainberg, Syma Iqbal, E. Gabriela Chiorean, Philip Philip. “SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in

patients with PD-L1 CPS ≥ 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE).” GI ASCO 2024

12. **Paul Eliezer Oberstein**, Meredith Pelster, Kerry Culm, Valerie Chamberlain Santos, Andrew Koustenis, Colleen M. Mockbee, Hagop Youssoufian, John C. Krauss. “ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress).” GI ASCO 2023. J Clin Oncol 41, 2023 (suppl 4; abstr TPS263)
13. **Paul Eliezer Oberstein**, Cathy Eng, Eric Van Cutsem, Elena Elez, Michel Ducreux, Sejal Patel, Dona Pang, Leann Milford, Ryota Iwasawa, Robert W. Schnepf, Roland Knoblauch, Meena Thayu. “A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer. GI ASCO 2023. J Clin Oncol 41, 2023 (suppl 4; abstr TPS279)
14. Chengwei Peng, Saad Saffo, Michael Shusterman, Daniel Jacob Becker, Jordan Berlin, **Paul Eliezer Oberstein**, Anil Nagar, Shun Yu. “Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.” GI ASCO 2023. J Clin Oncol 41, 2023 (suppl 4; abstr 59)
15. Deirdre Jill Cohen, Jonathan W Lee, Daniel Jacob Becker, Despina Siolas, Nina Beri, Theresa Ryan, Peter Kozuch, Shun Yu, Benjamin A. Levinson, Judith D. Goldberg, Lawrence P. Leichman, **Paul Eliezer Oberstein**. “Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naïve advanced gastric cancer following first line therapy.” ASCO 2023. J Clin Oncol 41, 2023 (suppl 16; abstr 4042)
16. J. Randolph Hecht, Scott Kopetz, Theodore Welling, Maria Pia Morelli, Julian R. Molina, Kedar Kirtane, **Paul Eliezer Oberstein**, Daniel R. Greenwald, Yi Lin, Armen Mardiros, Karl Beutner, Ariane Lozac'hmeur, Ameen Salahudeen, Kirstin B. Liechty, Judy Vong, Eric Wai-Choi Ng, David G. Maloney, William Y. Go, John Sutton Welch, Diane M. Simeone. “Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.” GI ASCO 2023. J Clin Oncol 41, 2023 (suppl 4; abstr 209)
17. Theodore S. Hong, Beow Y. Yeap, Nora K. Horick, Jennifer Yon-Li Wo, Colin D. Weekes, Jill N. Allen, Motaz Qadan, **Paul Eliezer Oberstein**, Rakesh K. Jain, Lawrence Scott Blaszkowsky, Brian M. Wolpin, Daniel A. Laheru, Wells A. Messersmith, Leilana Ly, Lorraine C. Drapek, David Tsai Ting, Richard A. Burkhart, Carlos Fernandez-del Castillo, Alec Kimmelman, David P. Ryan. “A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).” GI ASCO 2023. J Clin Oncol 41, 2023 (suppl 4; abstr 719)
18. **Paul E. Oberstein**; Osama Rahma; Nina Beri; Amy Stoll-D'Astice; Emily A. Kawaler; Igor Dolgalev; Gregor Werba; Victoire Cardo-Ruffino; Naïma Böllenrücher; Andressa Dias Costa; Saloney Nazeer; Matthew Squires; Jonathan Nowak; Dafna Bar-Sagi; Brian Wolpin; Diane M Simeone; Stephanie K Dougan. “Abstract PR005: Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1 β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis.” AACR Pancreatic Cancer Meeting Plenary Session, Oct 2022. Cancer Res (2022) 82 (22_Supplement): PR005.
19. Erkut Hasan Borazanci, Nathan Bahary, **Paul Eliezer Oberstein**, Vincent Chung, Roland T. Skeel, E. Gabriela Chiorean, Andrew E Greenstein, Hristina I Pashova, Iulia Cristina Tudor, Grace Mann. “A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.” ASCO 2022. J Clin Oncol 40, 2022 (suppl 16; abstr 4140)
20. Rachael A Safyan, Gulam Abbas Manji, Shing Mirn Lee, Rebecca Silva, Susan Elaine Bates, Ruth

Aroon White, Jacob K.R. Jamison, Adam Joel Bass, Gary K. Schwartz, **Paul Eliezer Oberstein**, Tamas Gonda. “Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.” ASCO 2022. J Clin Oncol 40, 2022 (suppl 16; abstr 4158)

21. **Paul Eliezer Oberstein**, Osama E. Rahma, Nina Beri, Amy C. Stoll-D'Astice, Anne-Marie Duliege, Saloney Nazeer, Matthew Squires, Dafna Bar-Sagi, Brian M. Wolpin, Stephanie Dougan, Diane M. Simeone. “A phase 1b study evaluating IL-1 β and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).” GI ASCO 2022. 10.1200/JCO.2022.40.4_suppl.557.
22. Daniel Weissinger; Emily A. Kawaler; Gregor Werba; Ende Zhao; Despoina Kalfakakou; Surajit Dhara; Grace Oh; Xiaohong Jing; Nina Beri; Lauren Khanna; Tamas Gonda; Paul E. Oberstein; Cristina Hajdu; Cynthia Loomis; Adriana Heguy; Mara H. Sherman; Amanda W. Lund; Theodore H. Welling; Igor Dolgalev; Aristotelis Tsirigos; Diane M. Simeone. “Abstract PR010: Single-cell sequencing elucidates the effects of chemotherapy on cancer cell heterogeneity and the tumor microenvironment of human pancreatic adenocarcinoma.” AACR Pancreatic Cancer Meeting 2022. Cancer Res (2022) 82 (22_Supplement): PR010.
23. Philip Agop Philip, Nathan Bahary, Amit Mahipal, Anup Kasi, Caio Max Sao Pedro Rocha Lima, Angela Tatiana Alistar, Paul Eliezer Oberstein, Talia Golan, Vaibhav Sahai, Jean Philippe Metges, Jill Lacy, Christos Fountzilas, Charles D. Lopez, Michel Ducreux, Pascal Hammel, Mohamed E. Salem, David Lawrence Bajor, Al Bowen Benson, Marc E. Buyse, Eric Van Cutsem. “Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).” ASCO 2022. J Clin Oncol 40, 2022 (suppl 16; abstr 4023)
24. Manuel Hidalgo; Teresa Macarulla; Valerya Semenisty; Erkut Borazanci; Jaime Feliu; Mariano Ponz-Sarvise; David Gutierrez Abad; Paul Oberstein; Angela Alistar; Andres Muñoz; Ravit Geva; Carmen Guillén-Ponce; Mercedes Salgado Fernandez; Amnon Peled; Marya Chaney; Irit Glicko-Kabir; Liron Shemesh-Darvish; Debby Ickowicz; Ella Sorani; Shaul E. Kadosh; Abi Vainstein-Haras; Bruno Bockorny. “Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC).” AACR Annual Meeting 2021. Cancer Res (2021) 81 (13_Supplement): CT177.
25. Pant, S; Chawla, S P; Chung, V; Del, Priore G; Kim, D W; Noel, M S; **Oberstein, P E**; Ocean, A J; Philip, P A; Picozzi, V J; Simeone, D M; Wang-Gillam, A. “Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC”. GI ASCO Meeting 2020. JCO.2020.38.4-5Fsuppl.TPS789.
26. Liu, J -Y; Placencio-Hickok, V; Anderson, B; **Oberstein, P E**; Coveler, A L; Denlinger, C S; Gong, J; Hendifar, A E. “Demoralization and depression in pancreatic cancer patients”. GI ASCO Meeting 2020. JCO.2020.38.4-5Fsuppl.TPS778
27. Mariano J. Alvarez; Yan Pengrong; Mary L. Alpaugh; Michaela Bowden; Ewa T. Sicinska; Chensheng W. Zhou; Charles Karan; Ronald B. Realubit; Prabhjot S. Mundi; Adina Grunn; Jager Dirk; John A. Chabot; Antonio T. Fojo; Paul E. Oberstein; Hanina Hibshoosh; Jeffrey W. Milsom; Matthew H. Kulke; Massimo Loda; Gabriela Chiosis; Diane L. Reidy-Lagunes; Andrea Califano. “Abstract LB-003: OncoMatch: Unbiased, quantitative assessment of cancer model fidelity for drug sensitivity and mechanism of action elucidation.” AACR Annual Meeting 2020. Cancer Res (2020) 80 (16_Supplement): LB-003.
28. **Paul Eliezer Oberstein**, Vilma Rosario, Xiaotao Guo, Binsheng Zhao, Jeanine M Genkinger, Michael D. Kluger, John A. Chabot. “Baseline and longitudinal quantification of lean muscle mass using routine CT measurements prior to resection for pancreatic adenocarcinoma.” GI ASCO 2019. DOI: 10.1200/JCO.2019.37.4_suppl.198 Journal of Clinical Oncology 37, no. 4_suppl (February 01, 2019) 198-198.

29. **Paul Eliezer Oberstein**, Beth Schrope, Tamas Gonda, Amrita Sethi, Arnold Han, Gary K. Schwartz, Manish A. Shah. A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma. J Clin Oncol 36, 2018 (suppl 4S; abstr TPS197), NCT02918162.
30. Rachael A Safyan, Tamas Gonda, Benjamin Tycko, John A. Chabot, Gulam Abbas Manji, Gary K. Schwartz, **Paul Eliezer Oberstein**. Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy. J Clin Oncol 36, 2018 (suppl 4S; abstr TPS534), NCT03264404.
31. Armando Del Portillo, **Paul Oberstein**, Alfred Neugut, David P Horowitz, Steven Lee-Kong, Daniel L Feingold, Ravi P Kiran, Antonia Sepulveda. Pathology Diagnosis of “At Least Intramucosal Adenocarcinoma” in Colorectal Biopsies of Mass Lesions Correlates with Advanced Tumor Stage (abs#710), Laboratory Investigation 2018; 98 (supple 1):257.
32. Yanghee Woo, Garrick Trapp, Jae Geun Hyun, Chul Soo Hyun, Lu Zen Katherine, Tamas Gonda, **Paul Eliezer Oberstein**, John A. Chabot, Timothy C. Wang. “Gastric cancer prevention and early detection program for an at-risk population: A prospective study of the Korean American community.” J Clin Oncol 33, 2015 (suppl 3; abstr 42).
33. **Paul Eliezer Oberstein**, Anthony Paul Gulati, Benjamin A Krantz, Rebecca Anne Moss, Stephen M. Schreiber, Dawn Tsushima, Kelley B Mowatt, John Allendorf, Beth Schrope, James A Lee, William H. Sherman, John A Chabot, Robert Fine. “The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy. Columbia University Medical Center experience.” J Clin Oncol 31, 2013 (suppl 4; abstr308).
34. **Oberstein PE**, Sandorf D, Cheng JD. “Fibroblast Activation Protein, an Epithelial Tumor Stromal Enzyme, Enhances Cytotoxicity of Proteasome Inhibitor Prodrugs.” The Ohio State University College of Medicine Graduate and Postgraduate Research Day, Columbus, Ohio, 2006. Poster presentation.

Patents

N/A